Related Experiment Video
Updated: Jul 7, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Clinical benefit of early anticoagulation in cardioembolic stroke
Sara Micheli1, Giancarlo Agnelli, Valeria Caso
1Stroke Unit, Department of Internal Medicine, University of Perugia, Perugia, Italy. saramicheli@hotmail.it
Insights
Early heparin administration for acute cardioembolic stroke is not supported by current evidence. However, recent findings suggest potential benefits within 3 hours, warranting further clinical trials for stroke treatment.
Area of Science:
- Cardiology
- Neurology
- Pharmacology
Background:
- Nonvalvular atrial fibrillation is a primary cause of cardiac embolism, leading to significant stroke risk and mortality.
- Managing acute stroke patients with identified cardiac embolism sources presents a clinical challenge regarding early anticoagulation.
- The dilemma involves balancing the risk of early stroke recurrence and mortality against the benefits of prompt anticoagulation.
Purpose of the Study:
- To review clinical trial evidence on the efficacy of early treatment for acute cardioembolic stroke.
- To evaluate the current understanding of anticoagulation timing in stroke patients with atrial fibrillation.
Main Methods:
- Systematic review of clinical trials investigating early treatment strategies for acute cardioembolic stroke.
- Analysis of data from large clinical trials concerning heparin administration in acute ischemic stroke.
Main Results:
- Large-scale clinical trials show no evidence to support heparin use in acute ischemic stroke patients within 48 hours of onset.
- Current evidence does not confirm the benefit of early heparin administration in this patient group.
Conclusions:
- While broad evidence does not support early heparin, recent studies indicate a potential advantage of very early administration (<3 hours).
- These findings encourage further clinical trials to explore the efficacy of early heparin in acute cardioembolic stroke.
- Further research is needed to establish optimal treatment protocols for acute cardioembolic stroke.
Background:
Nonvalvular atrial fibrillation is the most common source of cardiac embolism with a high reported risk of stroke and a high stroke-related mortality. A common clinical dilemma in patients with acute stroke is whether the detection of one of the major cardiac sources of emboli requires an early anticoagulation to reduce early stroke recurrence and mortality.
Methods:
In this review, we report on the results of clinical trials that have investigated the efficacy of early treatment for acute cardioembolic stroke.
Results:
Large clinical trials demonstrate that there is no evidence supporting the administration of heparin in patients with acute ischemic stroke within 48 h from stroke onset.
Conclusions:
The results of recent studies showing an advantage of the very early administration of heparin (<3 h from stroke onset) should encourage clinicians to perform further trials on the efficacy of an early administration of heparin in acute cardioembolic stroke.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hemorrhagic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
